Applied DNA Sciences Inc. (NASDAQ: APDN) stock jumped 46.43% on Friday to $4.10 against a previous-day closing price of $2.80. With 107.83 million shares changed hands, the volume of the stock remained heavier than its average volume of 2.01 million shares. During the session, the Diagnostics & Research company that operates in wider Healthcare sector, reached to the highest price of $5.7600 whereas the lowest price it dropped to was $3.5900. The 52-week range on APDN shows that it touched its highest point at $7.88 and its lowest point at $0.62 during that stretch. It currently has a 1-year price target of $11.33. Beta for the stock currently stands at 1.27.
Do You Know The Best Place To Find Gains In Volatile Markets?
In today's chaotic marketplace, the biggest gains will come from some currently-small companies that pass by older, larger businesses still stuck in a pre-pandemic world. The trick is figuring out which small caps will be tomorrow's winners. That's why StockWire News has put together a special Wealth Building Report, highlighting 3 small cap stocks set to soar in 2023.
Click here for full details and to join for free.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of APDN was up-trending over the past week, with a rise of 486.38%, but this was up by 400.73% over a month. Three-month performance surged to 167.97% while six-month performance rose 21.66%. The stock lost -39.79% in the past year, while it has gained 1.99% so far this year. A look at the trailing 12-month EPS for APDN yields -1.93 with Next year EPS estimates of -0.82. For the next quarter, that number is -0.32. This implies an EPS growth rate of 37.90% for this year and 38.90% for next year.
Float and Shares Shorts:
At present, 8.09 million APDN shares are outstanding with a float of 8.06 million shares on hand for trading. On Jul 14, 2022, short shares totaled 0.27 million, which was 3.05% higher than short shares on Jun 14, 2022. In addition to Dr. James A. Hayward Ph.D., Sc.D. as the firm’s Chairman, Pres & CEO, Ms. Beth M. Jantzen CPA, CPA serves as its Chief Financial Officer.
Through their ownership of 11.60% of APDN’s outstanding shares, institutional investors have minority control over the company. Other institutions hold 8.52% of APDN, in contrast to 5.13% held by mutual funds. Shares owned by individuals account for 3.90%. As the largest shareholder in APDN with 5.58% of the stake, Armistice Capital LLC holds 459,769 shares worth 459,769. A second-largest stockholder of APDN, The Vanguard Group, Inc., holds 210,226 shares, controlling over 2.55% of the firm’s shares. BlackRock Fund Advisors is the third largest shareholder in APDN, holding 81,991 shares or 1.00% stake. With a 1.46% stake in APDN, the Vanguard Total Stock Market Index is the largest stakeholder. A total of 120,114 shares are owned by the mutual fund manager. The Vanguard Extended Market Index Fu, which owns about 1.06% of APDN stock, is the second-largest Mutual Fund holder. It holds 87,412 shares valued at 64510.0. DFA US Micro Cap Portfolio holds 0.44% of the stake in APDN, owning 36,140 shares worth 26671.0.
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for APDN since 3 analysts follow the stock currently. There are 3 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 0 believe that the stock is worth HOLDING, 0 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential. With APDN analysts setting a high price target of $24.00 and a low target of $4.00, the average target price over the next 12 months is $11.33. Based on these targets, APDN could surge 485.37% to reach the target high and fall by -2.44% to reach the target low. Reaching the average price target will result in a growth of 176.34% from current levels.
EPS: Estimates vs Actual
It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. APDN will report FY 2022 earnings on 12/22/2022. Analysts have provided yearly estimates in a range of -$1.28 being high and -$1.50 being low. For APDN, this leads to a yearly average estimate of -$1.41. The earnings surprise of a firm occurs when the actual results change from the consensus earnings estimate. Applied DNA Sciences Inc. surprised analysts by $0.10 when it reported -$0.23 EPS against a consensus estimate of -$0.33. The surprise factor in the prior quarter was -$0.36. Based on analyst estimates, the high estimate for the next quarter is -$0.25 and the low estimate is -$0.36. The average estimate for the next quarter is thus -$0.32.
Summary of Insider Activity:
Insiders traded APDN stock several times over the past three months with 0 Buys and 0 Sells. In these transactions, 0 shares were bought while 0 shares were sold. The number of buy transactions has remained unchanged to 0 while that of sell transactions has remained unmoved to 0 over the past year. The total number of shares bought during that period was 0 while 0 shares were sold.